Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

NCT04450173

Conditions
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, +13 more
Locations
  • University of California, San Francisco (UCSF) Fresno Fresno, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California, San Diego San Diego, California, United States
View Trial Details
Active, not recruiting

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

NCT04911478

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Blood and Marrow Transplant Program Palo Alto, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Baylor Scott & White Research Institute Dallas, Texas, United States
  • MD Anderson Caner Center Houston, Texas, United States
View Trial Details
Active, not recruiting

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • City of Hope National Medical Center /ID# 273338 Duarte, California, United States
  • Valkyrie Clinical Trials /ID# 269935 Los Angeles, California, United States
  • Desert Regional Medical Center /ID# 272437 Palm Springs, California, United States
  • Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823 Golden, Colorado, United States
View all 176 locations
View Trial Details
Active, not recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details
Active, not recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660

Conditions
Burkitt Lymphoma, DNA Virus Infections, Disease Attributes, +19 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Diego Health (UCSD) La Jolla, California, United States
  • University of California Davis (UC Davis) Sacramento, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 34 locations
View Trial Details
Active, not recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

NCT05798156

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Uniklinik Innsbruck Innsbruck, Austria
  • Kepler Universitätsklinikum Linz, Austria
  • Ordensklinikum Linz - Barmherzige Schwestern Linz, Austria
  • Ordensklinikum Linz - Elisabethinen Linz, Austria
View all 28 locations
View Trial Details
Active, not recruiting

Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

NCT03993912

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Chru Jean Minjoz Besançon, France
  • Ch Blois Simone Veil Blois, France
  • Ch Fleyriat Bourg-en-Bresse, France
  • Chru Brest Site Hopital Morvan Brest, France
View all 23 locations
View Trial Details

Related conditions